Vertex Pharmaceuticals Inc (VRTX) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Tr...
Vertex Pharmaceuticals Inc's revenue increased 8.9% year over year, from $11.02B to $12.00B.
Net income increased 838.1% over the same period, from $-535.6M to $3.95B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 605% in total.
Operating cash flow grew 837.2% to $3.63B.
Vertex Pharmaceuticals Inc maintains a strong net profit margin of 32.9%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $7.35B+51.0% | $2.65B | $6.46B | $2.84B | $3.30B | $21.73B | N/A | $16.51B |
| Q1 FY2024 | $2.69B-63.4% | $1.10B | $2.35B | $1.14B | $1.31B | $23.92B | N/A | $18.55B |
| Q2 FY2024 | $5.34B+98.3% | $-2.49B | $4.62B | $-2.38B | $-2.45B | $20.13B | N/A | $14.77B |
| Q3 FY2024 | $8.11B+51.9% | $-1.45B | $7.00B | $-1.26B | $-1.08B | $22.24B | N/A | $15.63B |
| Q1 FY2025 | $2.77B-65.8% | $646.3M | $2.41B | $630.1M | $818.9M | $22.88B | N/A | $16.50B |
| Q2 FY2025 | $5.73B+107.0% | $1.68B | $4.96B | $1.78B | $1.89B | $24.04B | N/A | $17.18B |
| Q3 FY2025 | $8.81B+53.6% | $2.76B | $7.63B | $2.97B | $3.13B | $24.86B | N/A | $17.32B |
| Q1 FY2026 | $2.99B-66.1% | $1.03B | $2.59B | $1.14B | $1.43B | $26.48B | N/A | $19.36B |
Balance Sheet Summary (Latest Period)
Total Assets
$25.64B
Total Liabilities
$6.98B
Total Equity
$18.67B
Cash & Equivalents
$6.61B
Total Debt
N/A
Current Assets
$11.20B
Current Liabilities
$3.86B
Retained Earnings
$13.56B